Langley SEM, Laing R. Prostate Brachytherapy has come of age: A review of the techniques and results.
British Journal of Urology International 2002. 89(2) 1-14.

Henderson A, Cahill D, Laing RW Langley SEM. Iodine125 Prostate Brachytherapy: Selection strategies outcome from our first 100 consecutive patients.
British Journal of Urology International 2002. 90(6) 567-572.

Henderson A, Laing RW, Langley SEM. A spanner in the works; the use of a new temporary urethral stent to relieve bladder outflow obstruction following prostate brachytherapy.
Brachytherapy 2002 1(4) 211-218.

Henderson A, Laing RW, Langley SEM. Is Bicalutamide equivalent to goserelin for prostate volume reduction prior to prostate brachytherapy.
Clinical Oncology 2003; 15: 318-321

Henderson A, Laing RW, Langley SEM.
Intraoperative identification of pubic arch interference in prostate brachytherapy: simplifying the transrectal ultrasound technique. Brachytherapy 2003; 2(4) 240-245

Bott S, Henderson A, Laing RW, Parkinson C, Langley SEM.
Setting up a prostate cancer database: how to get out more than you put in.
British Journal of Urology International 2003; 92(7) 665

Henderson A, Laing RW, Langley SEM.
Quality of Life following Treatment for Early Prostate Cancer : Does Brachytherapy offer a better quality of life?
European Urology 2004; 45 134-141

Langley SEM, Henderson A, Laing RW.
The SPIRIT of research: A new well-funded randomised study comparing brachytherapy to radical prostatectomy is about to open in the UK.
British Journal of Urology International 2004 Jan;93(1):6-7.

Bott S, Henderson A, McLarty E, Langley SEM.
A brachytherapy template approach to standardize saturation prostatic biopsy.
British Journal of Urology International 2004; 93(4) 662

Langley SEM, Laing RW, Henderson A et al. European Collaborative Group on Prostate
Brachytherapy: Preliminary Report in 1175 Patients.
European Urology 2004; 46(5) 565-570

Henderson A, Ismail A, Cunningham M, Aldridge S, Loverock L, Langley SEM, Laing RW.
Toxicity and early biochemical outcomes from 125Iodine prostate brachytherapy: a prospective study.
Clinical 2004; 16(2) 95-104

Sooikumaran P, Henderson A, Laing RW, Langley SEM. Ofrece la braquiterapia major Calidad de vida que otros tratamientos radicales para lospacientes con cancer de prostata?
Rev. Urol. 2004; 5(2): 83-89

Sooikumaran P, Henderson A, Laing RW, Langley SEM. Quality of Life Issues with Prostate Brachytherapy
Urology News 2004; 8(5): 12-17

Henderson A, Andrich DEA, Pietrasik ME, Higgins D, Montgomery B, Langley SEM. Outcome analysis and patient satisfaction following octant transrectal ultrasound-guided prostate biopsy: A prospective study comparing consultant urologist, specialist registrar and nurse practitioner in urology.
Prostate Cancer and Prostatic Diseases 2004; 7,122-125

Sooriakumaran P, Lovell D, Henderson A, Laing R, Langley SEM.
Gleason scoring varies among pathologists, and this affects clinical risk in prostate cancer patients.
Clinical Oncology 2005 Dec; 17(8): 655-658

Simon R.J. Bott, Alastair Henderson, Robert W. Laing, Bruce S.I. Montgomery, SEM Langley.
Technical considerations when obtaining and interpreting prostatic biopsies from men with a suspicion of early prostate cancer.
British Journal of Urology International 2005: Sep 96(4); 686-686

Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE. Extensive transperineal template biopsies of prostate: modified technique and results.
Urology. 2006 Nov;68(5):1037-41. Epub 2006 Nov 7

Khaksar SJ, Laing RW, Henderson A, Sooriakumaran P, Lovell D, Langley SE.
Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate. prostate brachytherapy.
BJU Int. 2006 Dec;98(6):1210-5. Epub 2006 Oct 11.

Guedea F, Aguilo F, Polo A, Langley S, Laing R, Henderson A, Aaltomaa S, Kataja V, Palmgren J, Bladou F, Salem N, Serment G, Nava L, Losa A, Guazzoni G.
Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer.
Radiotherapy and Oncology July 2006; 80: 57–61

Bott SRJ, Foley CL, Bull MD, Reddy CJ, Freeman A, Montgomery BSI, Langley SEM.
Are prostatic biopsies necessary in men over 80?
BJU Int. 2007 Feb;99(2):335-8.

Langley SEM
Permanent low-dose rate prostate brachytherapy
Ann R Coll Surg Engl 2006 88; 442-444

Khaksar SJ, Langley SEM, , Lovell D, Laing RW,
Interstitial low dose rate brachytherapy for prostate cancer – A focus on Intermediate and High Risk disease
Clin Oncol (R Coll Radiol). 2006 Sep;18(7):513-8.

Nobes J, Laing RW, Langley SEM.
An overview of I-125 prostate brachytherapy for early prostate cancer.
Urology 2007; 12(1):7-9.

Nobes J, Laing RW, Langley SEM.
The value of day 1 imaging following LDR prostate brachytherapy.
Radiother Oncol 2008; 86(2):288-9.

Voulgaris S, Nobes J, Laing RW, Langley SEM.
State of the art: prostate LDR brachytherapy.
Prostate Cancer Prostatic Dis. 2008 March 25;11(3):237-40.

Nobes J, Wells IG, Khaksar S, Money-Kyrle J, Laing RW, Langley SEM.
Biochemical relapse free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
Prostate Cancer Prostatic Dis. 2009;12(1):61-6. Epub 2008 Apr 22.

Nobes J, Laing RW, Langley SEM.
Male health and the metabolic syndrome.
Urology 2008;12(4):6-10.

Nobes J, Khaksar S, Hawkins M, Cunningham M, Langley SEM, Laing RW.
Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Radiother Oncol 2008 Jul:88(1): 121-6.

Nobes J, Langley SEM, Laing RW.
Metabolic Syndrome and Prostate Cancer: A Review.
Clin Oncol (R Coll Radiol). 2009 Apr;21(3):183-91. Epub 2008 Dec 25.

Ferran Guedea, Ferran Aguilo, Alfredo Polo, Stephen Langley, Robert Laing, Alastair Henderson, Sirpa Aaltomaa, Vese Kataja, Juni Palmgren, Franch Bladou, Naji Salem, Gwenaelle Gravis, Andrea Losa, Giorgio Guazzoni, Luciano Nava.
Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer.
Radiother Oncol. 2006 Jul;80(1):57-61. Epub 2006 Jul 10.

J. Nobes, I.G. Wells, S. Khaksar, J.F. Money-Kyrle, R.W. Laing, S.E.M. Langley.
Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
Prostate Cancer Prostatic Dis. 2009;12(1):61-6. Epub 2008 Apr 22.

Sooriakumaran P, Henderson A, Denham P, Langley SEM. A novel method of obtaining prostate tissue for gene expression profiling
Int J Surg Pathol. 2009 Jun;17(3):238-43. Epub 2008 May 28.

Bott S, Langley S, Hindley R, Montgomery B. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.
BJU Int. 2009 Mar;103(5):701.

Sooriakumaran P, Macanas-Pirard P, Bucca G, Henderson A, Langley SE, Laing RW, Smith CP, Laing EE, Coley HM. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.
Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):93-9.

Nobes JP, Langley SE, Laing RW Metabolic syndrome and prostate cancer: a review..
Clin Oncol (R Coll Radiol). 2009 Apr;21(3):183-91. Epub 2008 Dec 25.

S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R.
Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau A multi-institutional evaluation of active surveillance for low-risk prostate cancer.
J Urol 2009; 181: 1635-1641.

Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, Eden CG, Miller PD, Langley SE, Laing RW. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
Anticancer Res. 2009 May;29(5):1483-8.

Bott SJ Langley SEM
Prostate Cancer; ABC of Urology,
Third Edition. Ed Dawson & Nethercliffe. c 2012 John Wiley & Sons, Ltd.

4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds. Langley SE, Laing RW.
BJU Int. 2012 Feb;109 Suppl 1:1-6. doi: 10.1111/j.1464-410X.2011.10824.x.

Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.
Langley SEM, Ahmed H, Al-Qaisieh3 B, Bostwick D, Dickinson L, Francisco Veiga G, Grimm
P, Machtens S, Guedea F, Emberton M.
BJU Int. 2012 Feb;109 Suppl 1: 7-16

Grimm P, Billiet I, Bostwick D, Dicker A, Frank S, Immerzee J, Keyes M, Kupelian P,
Lee W, Machtens S, Mayadev J, Moran B, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R Langley SEM.

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group
BJU Int. 2012 Feb;109 Suppl 1: 22-30

Pandha H , Sorensen K , Thorsten F. Orntoft T , Langley SEM, Hoyer S , Borre M, Morgan R. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.
BJU Int. 2012 | doi:10.1111/j.1464-410X.2012.11208.x

Emara AM, Chadwick E, Nobes JP, Abdelbaky AM, Laing RW, Langley SE.
Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer.
BJU Int. 2012 Apr;109(7):994-1000.

Ayres BE, Montgomery BS, Barber NJ, Pereira N, Langley SE, Denham P, Bott SR. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance.
BJU Int. 2012 Apr;109(8):1170-6.

Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW.
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
BJU Int. 2012 May;109(10):1495-502.

Earley JJ, Abdelbaky AM, Cunningham MJ, Chadwick E, Langley SE, Laing RW.
Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: A matched case-control study.
Radiother Oncol. 2012 Aug;104(2):187-91.

Saqib Javed, Stephen Langley The importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection.’
BJU Int. 2014 113(4) 535-40

Saqib Javed, Eliot Chadwick, Sabeena Beveridge, Simon Bott, Christopher Eden and Stephen Langley Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int 2014; 114: 541–548

Hardev Pandha*, Saqib Javed*, Prasanna Sooriakumaranc, Simon Bott, Bruce Montgomery, Anthony Hutton, Christopher Eden, Stephen E. Langley & Richard Morgan. Correlation of urinary engrailed-2 levels to tumour volume and pathological stage in men undergoing radical prostatectomy.’
Journal of Cancer Therapy, 2013, 4, 726-733

Saqib Javed, Stephen E.M. Langley The importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection.
UroToday.com, 7 March 2014

A.Edwards, R. Laing, and S. Langley Favourable long-term outcomes with brachytherapy-based regimens in men <60 years with clinically localized prostate cancer. BJU Int,111(8):1181–1182, Jun 2013.

P Brousil, M Hussain, M Lynch, RW Laing & SEM Langley. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible, BJU Int. 2015 115: 580-586
Kirby M, Langley S, McNicholas T, Newman J, Smith C, Sahai A, Trueman E, Payne H

Integrative review on the non-invasive management of lower urinary tract symptoms (LUTS) in men following treatments for pelvic malignancies.
Int J Clin Pract, October 2015, 69, 10, 1184–1208

Al-Qaisieh B, Mason J, Bownes P, Henry A, Dickinson L, Ahmed HU, Emberton M, Langley SE. Dosimetry modeling for focal low-dose-rate prostate brachytherapy.
IJROBP 2015; 92(4):787-93

SEM Langley, J Uribe, BJ Challacombe and SRJ Bott. A practical approach to investigating a man with a raised prostate-specific antigen in the modern era
Journal of Clinical Urology 2016, Vol. 9(6) 417 –42

Laing R, Uribe J, Uribe-Lewis S, Money-Kyrle J, Perna C, Chintzoglou S, Khaksar S, Langley SEM Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
BJU Int. 2018 Oct;122(4):610-617

Langley SEM, Soares R, Uribe J, Uribe-Lewis S, Money-Kyrle J, Perna C, Khaksar S, Laing R, Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
BJU Int. 2018 Jan;121(1):38-45.

Langley SEM, Uribe J, Uribe-Lewis S, Money-Kyrle J, Perna C, Khaksar S, Soares R, Laing R. Comparative analysis of clinical outcomes and procedural costs between the conventional two stage technique and 4D Brachytherapy for early prostate cancer.
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):57-64.

Langley SEM, Uribe J, Uribe-Lewis S, Franklin A, Perna C, Horton A, Cunningham C, Higgins D, Deering C, Khaksar S, Laing R Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer.
BJU Int 2020 Mar;125(3):383-390

Abou Chedid W, Nason GJ, Evans AT, Yamada K, Moschonas D, Patil K, Langley SEM,
Perry MJA The impact of COVID-19 on surgical volume and surgical training at a high volume pelvic oncology centre. Urologia. 2021 Dec 8;3915603211062827. doi:
10.1177/03915603211062827

Uribe-Lewis S, Uribe J, Bourke V, Deering C, Higgins D, Mehta S, Mikropoulos C, Sophie Otter,Perna C, Khaksar S, Laing R, Langley SEM. Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience. BJU Int 2022 129 (6): 723-73

Uribe-Lewis S, Uribe J, Deering C, Langley S, Higgins D, Whiting D, Metawe M, Khaksar S, Mehta S, Mikropoulos C, Sophie Otter, Perna C, Langley SEM. Net survival of men with localized prostate cancer after LDR brachytherapy. Brachytherapy 2024 23(3): 239-334